Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chronic lymphocytic leukemia treatment

G Dighiero1

  • 1Institut Pasteur, Unité d'Immuno-Hématologie et d'Immunopathologie, Paris, France.

Hematology and Cell Therapy
|February 21, 1998
PubMed
Summary

For early-stage chronic lymphocytic leukemia (CLL), deferring treatment until progression is recommended over early intervention. Purine analogues show efficacy as first-line therapy, offering better response rates than chlorambucil but not improving overall survival.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Monoclonal and/or Oligoclonal Immunoglobulins in Sera of Patients with Non-Hodgkin's Lymphomas, Determined by Iso-Electric Focusing and Immunoblotting.

Leukemia & lymphoma·2016
Same author

B Cell Malignancies Frequently Target the Autoreactive B Cell Repertoire.

Leukemia & lymphoma·2016
Same author

Activation of the PI3K/AKT pathway by microRNA-22 results in CLL B-cell proliferation.

Leukemia·2014
Same author

"Role of the B-cell receptor and the microenvironment in chronic lymphocytic leukemia''.

Blood cancer journal·2013
Same author

Lipoprotein lipase expression in unmutated CLL patients is the consequence of a demethylation process induced by the microenvironment.

Leukemia·2012
Same author

Chronic lymphocytic leukaemia.

Lancet (London, England)·2008

Area of Science:

  • Hematology
  • Oncology
  • Clinical Trials

Background:

  • Investigating optimal treatment strategies for early-stage chronic lymphocytic leukemia (CLL).
  • Evaluating the efficacy and survival impact of chlorambucil (CB) versus deferring treatment.
  • Assessing the role of purine analogues as first-line therapy in CLL.

Framework:

  • Analysis of randomized trials and meta-analyses for early-stage CLL.
  • Review of long-term data from non-randomized and randomized studies of purine analogues (fludarabine and 2-chloro-deoxyadenosine).
  • Comparison of treatment outcomes including response rates, progression-free intervals, and overall survival.

Implementation:

  • Conventional chlorambucil schedules do not prolong survival in early-stage CLL; deferring treatment until progression is advisable.
  • High-dose continuous chlorambucil may offer symptom relief.
  • Purine analogues demonstrate high overall response rates (>75%) and complete remissions (~25%) in CLL.

Implications:

  • Purine analogues are effective first-line agents for CLL, showing superior response rates compared to chlorambucil.
  • While purine analogues improve response, they do not cure CLL and do not significantly improve overall survival.
  • Future research should focus on molecular remission and combination therapies, including transplantation and biological modifiers, for improved long-term outcomes in high-risk CLL patients.

Related Experiment Videos